431 related articles for article (PubMed ID: 33092220)
21. Activation of microglia by retroviral infection correlates with transient clearance of prions from the brain but does not change incubation time.
Muth C; Schröck K; Madore C; Hartmann K; Fanek Z; Butovsky O; Glatzel M; Krasemann S
Brain Pathol; 2017 Sep; 27(5):590-602. PubMed ID: 27558169
[TBL] [Abstract][Full Text] [Related]
22. Persistent retroviral infection with MoMuLV influences neuropathological signature and phenotype of prion disease.
Krasemann S; Neumann M; Luepke JP; Grashorn J; Wurr S; Stocking C; Glatzel M
Acta Neuropathol; 2012 Jul; 124(1):111-26. PubMed ID: 22271154
[TBL] [Abstract][Full Text] [Related]
23. Oral Prion Neuroinvasion Occurs Independently of PrP
Marshall A; Bradford BM; Clarke AR; Manson JC; Mabbott NA
J Virol; 2018 Oct; 92(19):. PubMed ID: 30021891
[TBL] [Abstract][Full Text] [Related]
24. A Fluorescent Oligothiophene-Bis-Triazine ligand interacts with PrP fibrils and detects SDS-resistant oligomers in human prion diseases.
Imberdis T; Ayrolles-Torro A; Duarte Rodrigues A; Torrent J; Alvarez-Martinez MT; Kovacs GG; Verdier JM; Robitzer M; Perrier V
Mol Neurodegener; 2016 Jan; 11():11. PubMed ID: 26809712
[TBL] [Abstract][Full Text] [Related]
25. Prion disease pathogenesis in the absence of the commensal microbiota.
Bradford BM; Tetlow L; Mabbott NA
J Gen Virol; 2017 Jul; 98(7):1943-1952. PubMed ID: 28708055
[TBL] [Abstract][Full Text] [Related]
26. Neuroinflammation, Microglia, and Cell-Association during Prion Disease.
Carroll JA; Chesebro B
Viruses; 2019 Jan; 11(1):. PubMed ID: 30650564
[TBL] [Abstract][Full Text] [Related]
27. Soluble dimeric prion protein binds PrP(Sc) in vivo and antagonizes prion disease.
Meier P; Genoud N; Prinz M; Maissen M; Rülicke T; Zurbriggen A; Raeber AJ; Aguzzi A
Cell; 2003 Apr; 113(1):49-60. PubMed ID: 12679034
[TBL] [Abstract][Full Text] [Related]
28. The disulfide isomerase Grp58 is a protective factor against prion neurotoxicity.
Hetz C; Russelakis-Carneiro M; Wälchli S; Carboni S; Vial-Knecht E; Maundrell K; Castilla J; Soto C
J Neurosci; 2005 Mar; 25(11):2793-802. PubMed ID: 15772339
[TBL] [Abstract][Full Text] [Related]
29. Prion protein self-interactions: a gateway to novel therapeutic strategies?
Rigter A; Langeveld JP; van Zijderveld FG; Bossers A
Vaccine; 2010 Nov; 28(49):7810-23. PubMed ID: 20932496
[TBL] [Abstract][Full Text] [Related]
30. The N-Terminal Polybasic Region of Prion Protein Is Crucial in Prion Pathogenesis Independently of the Octapeptide Repeat Region.
Das NR; Miyata H; Hara H; Chida J; Uchiyama K; Masujin K; Watanabe H; Kondoh G; Sakaguchi S
Mol Neurobiol; 2020 Feb; 57(2):1203-1216. PubMed ID: 31707632
[TBL] [Abstract][Full Text] [Related]
31. Celecoxib Inhibits Prion Protein 90-231-Mediated Pro-inflammatory Responses in Microglial Cells.
Villa V; Thellung S; Corsaro A; Novelli F; Tasso B; Colucci-D'Amato L; Gatta E; Tonelli M; Florio T
Mol Neurobiol; 2016 Jan; 53(1):57-72. PubMed ID: 25404089
[TBL] [Abstract][Full Text] [Related]
32. Increased Gal-3 Mediates Microglia Activation and Neuroinflammation via the TREM2 Signaling Pathway in Prion Infection.
Fan Q; Wu YZ; Jia XX; A R; Liu CM; Zhang WW; Chao ZY; Zhou DH; Wang Y; Chen J; Xiao K; Chen C; Shi Q; Dong XP
ACS Chem Neurosci; 2023 Oct; 14(20):3772-3793. PubMed ID: 37769016
[TBL] [Abstract][Full Text] [Related]
33. A transmembrane form of the prion protein in neurodegenerative disease.
Hegde RS; Mastrianni JA; Scott MR; DeFea KA; Tremblay P; Torchia M; DeArmond SJ; Prusiner SB; Lingappa VR
Science; 1998 Feb; 279(5352):827-34. PubMed ID: 9452375
[TBL] [Abstract][Full Text] [Related]
34. Amyloid associated proteins in Alzheimer's and prion disease.
Veerhuis R; Boshuizen RS; Familian A
Curr Drug Targets CNS Neurol Disord; 2005 Jun; 4(3):235-48. PubMed ID: 15975027
[TBL] [Abstract][Full Text] [Related]
35. Inflammatory response of microglia to prions is controlled by sialylation of PrP
Srivastava S; Katorcha E; Makarava N; Barrett JP; Loane DJ; Baskakov IV
Sci Rep; 2018 Jul; 8(1):11326. PubMed ID: 30054538
[TBL] [Abstract][Full Text] [Related]
36. Study on the toxic mechanism of prion protein peptide 106-126 in neuronal and non neuronal cells.
Dupiereux I; Zorzi W; Rachidi W; Zorzi D; Pierard O; Lhereux B; Heinen E; Elmoualij B
J Neurosci Res; 2006 Aug; 84(3):637-46. PubMed ID: 16786576
[TBL] [Abstract][Full Text] [Related]
37. Targeting prion proteins in neurodegenerative disease.
Gilch S; Krammer C; Schätzl HM
Expert Opin Biol Ther; 2008 Jul; 8(7):923-40. PubMed ID: 18549323
[TBL] [Abstract][Full Text] [Related]
38. Disease-associated protein seeding suggests a dissociation between misfolded protein accumulation and neurodegeneration in prion disease.
Alibhai J; Diack A; Manson J
Prion; 2017 Nov; 11(6):381-387. PubMed ID: 29023184
[TBL] [Abstract][Full Text] [Related]
39. Novel amplification mechanism of prions through disrupting sortilin-mediated trafficking.
Sakaguchi S; Uchiyama K
Prion; 2017 Nov; 11(6):398-404. PubMed ID: 29099278
[TBL] [Abstract][Full Text] [Related]
40. The prion's elusive reason for being.
Aguzzi A; Baumann F; Bremer J
Annu Rev Neurosci; 2008; 31():439-77. PubMed ID: 18558863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
